

PATRYS LIMITED
(ASX:PAB)

CHAIRMAN'S ADDRESS
2007 ANNUAL GENERAL MEETING

Ladies and Gentlemen, welcome to the inaugural Annual General Meeting of Patrys Limited. Let me begin by introducing my fellow directors, declaring the meeting officially open and addressing the statutory requirements for today's meeting.

This is a profound year in the development of your Company, no better exemplified than by Patrys' recent successful IPO raising of \$25 million and listing on the ASX. On behalf of my fellow directors I extend a vote of appreciation to all shareholders for their support of the Company's IPO and their continued interest in the Company's development.

Without detracting from the importance of the Company's capital initiatives, I consider it equally important to draw your attention to a number of the important steps Patrys has undertaken during the year, namely:

- The advancement of our lead product candidates including the generation and collation of a significant body of data to support manufacturing processes and the regulatory process for clinical trials;
- The expansion of our lead product pipeline and the progression of these lead candidates through development milestones;
- Establishment of an appropriate corporate and governance structure including independent directors and an international advisory team of biopharmaceutical experts to guide Patrys' product development; and
- The development of existing and new commercial relations with world leading pharmaceutical companies including AstraZeneca and Takeda Pharmaceutical Company to enhance several of the Company's natural human antibody therapeutic product candidates.

For the investor who will allow the Company to achieve its milestones according to the timeline set forth in the Company's Prospectus, I am of the view that Patrys offers a unique proposition as highlighted by the following key Company specific attributes:

- **Novel Technology in one of biotechnology's largest and fastest growing segments.** Patrys' enjoys two unique technology advantages relative to its competitors in the multi-billion dollar antibody market. First its underlying technology platform which is based on proprietary natural human antibodies. Human antibodies are considered the next generation of therapeutic antibodies and are expected to offer highly targeted, safer and more effective treatment options. When this proprietary platform is coupled with the Company's deep product pipeline of 12 products in lead development programs and over 260 back-up anti-cancer human antibodies, it highlights to me the very significant value inherent in Patrys' intellectual property.
- **Targets Life Threatening Diseases.** Patrys' human antibodies target life threatening diseases. These unmet medical needs in turn offer substantial market opportunities. More specifically, the Company's main programs target cancer, where the life expectancy of patients has not increased substantially in over 20 years. As a consequence the demand for new classes of effective cancer treatments remains high. And antibody therapies have made significant headway in this field, as several anti-cancer antibodies on the market now have sales in excess of \$1 billion annually.

- **Diversification.** Patrys enjoys an enviable position amongst its industry peers. This reflects not only the breadth of applications targeted by the Company's antibodies and the depth of its library of cell lines but arguably of more significant interest to Patrys' shareholders is the commercial diversification represented by the full range of development stages from research, through product development to commercial collaboration currently being undertaken by the Company.
- **Demand Exceeding Supply** There is immense demand for antibody products by major pharmaceutical and biotechnology companies as demonstrated by the large number of recent transactions involving antibody companies of all stages, including emerging antibody companies. Patrys is ideally positioned to leverage shareholder value by exploiting the demand created by these large industry players in a market characterized by a diminishing number of antibody therapeutic development companies.

Before passing over to our CEO, Dan Devine, who will provide a more comprehensive presentation on the Company's achievements and outlook, I would like to briefly touch on the key milestones anticipated over the next 18 months.

In addition to furthering our existing commercial partnerships it is fundamental to the Company's future that Patrys targets the commencement of its first human clinical trials of its two lead anti-cancer human therapeutic antibodies by the end of 2008. This objective is not without risks.

There are many important steps to achieving this ambitious target. Paramount amongst them is the establishment of manufacturing processes and the completion of the remaining preclinical trails necessary to achieve regulatory approval for human clinical trails. We look forward to reporting regularly as we make progress in these key fields of endeavour.

JOHN D. READ
CHAIRMAN
20 NOVEMBER 2007